Pfenex Inc. (PFNX)

Home » Stocks » PFNX

Sep 30, 2020 - PFNX was delisted after being acquired by LGND

Stock Price: $12.75 USD 0.00 (0.00%)

Updated Sep 30, 2020 4:00 PM EDT

• Overview
• News
• Financials

Key Info

Market Cap	437.28M
Revenue (ttm)	38.62M
Net Income (ttm)	-8.13M
Shares Out	34.30M
EPS (ttm)	-0.18
PE Ratio	n/a
Forward PE	42.37
Dividend	n/a
Dividend Yield	n/a

Stock Quote

Trading Day	Sep 30, 2020
Last Price	$12.75
Previous Close	$12.75
Change ($)	0.00
Change (%)	0.00%
Day's Open	-
Day's Range	12.74 - 12.94
Day's Volume	0
52-Week Range	5.26 - 14.00

More Stats

Market Cap	437.28M
Enterprise Value	379.38M
Earnings Date (est)	Nov 12, 2020
Ex-Dividend Date	n/a
Shares Outstanding	34.30M
Float	34.15M
EPS (basic)	-0.22
EPS (diluted)	-0.18
FCF / Share	-0.16

Dividend	n/a
Dividend Yield	n/a
Earnings Yield	n/a
FCF Yield	n/a
Payout Ratio	n/a
Shares Short	539,032
Short Ratio	0.93
Short % of Float	1.58%
Beta	1.32

PE Ratio	n/a
Forward PE	42.37
P/FCF Ratio	n/a
PS Ratio	11.32
PB Ratio	5.90
Revenue	38.62M
Operating Income	-8.28M
Net Income	-8.13M
Free Cash Flow	-5.54M

Net Cash	57.91M
Net Cash / Share	1.69
Gross Margin	110.50%
Operating Margin	-21.43%
Profit Margin	-21.10%
FCF Margin	-14.34%
ROA	-4.95%
ROE	-9.22%
ROIC	-59.40%

Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (3)

Buy	0
Overweight	0
Hold	3
Underweight	0
Sell	0

What these ratings mean

Analyst Consensus: Hold

Price Target

$14.67*

(15.06% upside)

Low

13.0

Current: $12.75

High

18.0

Target: 14.67

*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Income Statement | Balance Sheet | Cash Flow

Year	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	50.33	14.86	28.78	60.19	9.58	10.64	11.91	11.29
Revenue Growth	238.74%	-48.38%	-52.19%	528.13%	-9.97%	-10.66%	5.49%	-
Gross Profit	45.44	9.84	23.62	54.88	4.94	3.41	5.49	4.04
Operating Income	0.82	-39.85	-25.98	5.12	-27.84	-9.72	-6.70	-4.63
Net Income	1.06	-39.59	-25.68	5.48	-28.22	-9.79	-4.06	-2.59
Shares Outstanding	31.60	28.34	23.50	23.39	22.38	9.44	1.53	1.47
Earnings Per Share	0.03	-1.40	-1.09	0.23	-1.26	-1.04	-3.76	-2.84
Operating Cash Flow	-4.13	-39.43	-21.51	-22.27	24.23	-10.00	-4.60	-2.89
Capital Expenditures	-0.85	-1.47	-2.20	-2.86	-1.47	-0.32	-0.11	-0.32
Free Cash Flow	-4.97	-40.90	-23.71	-25.13	22.76	-10.32	-4.71	-3.21
Cash & Equivalents	55.82	56.42	57.86	81.50	110	49.68	9.23	11.47
Total Debt	3.85	0.51	0.65	0.08	3.81	3.81	3.59	1.14
Net Cash / Debt	51.98	55.91	57.22	81.42	106	45.86	5.64	10.33
Assets	84.89	81.28	79.39	103	132	71.02	31.81	32.93
Liabilities	12.59	20.14	21.63	22.98	60.51	11.15	13.08	10.29
Book Value	72.30	61.14	57.76	80.15	71.18	59.87	-94.45	-19.86

Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name	Pfenex Inc.
Country	United States
Employees	88
CEO	Evert B. Schimmelpennink

Stock Information

Ticker Symbol	PFNX
Stock Exchange	NYSE American
Sector	Healthcare
Industry	Biotechnology
Unique Identifier	NYSEAMERICAN: PFNX
IPO Date	July 24, 2014

Description

Pfenex, a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidate include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis. The company also develops PF743, a recombinant crisantaspase; PF745, a recombinant crisantaspase with half-life extension technology; and PF810, a peptide based next generation therapeutic which is in preclinical development, as well as offers sparX-1 (PF753) and sparX-2 (PF754). In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.